PRMT5 and neoplasm: Therefore, MTA-cooperative PRMT5 inhibitors have the ability to inhibit tumor cells potently while avoid the hematological toxicity commonly caused by first-generation, non-MTA cooperative PRMT5 inhibitors, such as GSK3326595 and JNJ64619178 (64, 65).